Apollomics (APLM) AI Stock Analysis

Apollomics

(NASDAQ:APLM)

Select Model

Rating:39Underperform

Price Target:$19.00▼(-8.17% Downside)

Action:downgraded

Date:10/27/26

Apollomics receives a deeply bearish overall score of 39, driven primarily by severe financial instability and persistent unprofitability. While revenue growth is a positive standout, negative equity and ongoing cash burn present acute liquidity risks. Compounding these fundamental issues, technical indicators show strong downward momentum, though deeply oversold signals suggest a potential short-term stabilization. A negative P/E ratio further underscores the structural risks typical of early-stage biotech investments.

Positive Factors

Revenue ExpansionThe sharp increase in annual revenue indicates improved commercial or partnering traction and gives the pipeline greater economic relevance. If this activity can be repeated, it may provide additional funding for development and strengthen the company’s ability to advance candidates toward approval.

Negative Factors

Persistent LossesApollomics remains deeply unprofitable despite the increase in revenue, showing that current activity does not yet cover operating costs. Continued losses can consume resources needed for clinical development and leave future performance highly dependent on successful partnering, approvals, or financing.

Apollomics (APLM) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $60.31M
Dividend Yield: ―
Average Volume (3M): 19.39K
Price to Earnings (P/E): -2.7
Beta (1Y): 0.92
Revenue Growth: ―
EPS Growth: 86.10%
Country: US
Employees: 14
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Apollomics Business Overview & Revenue Model

Company Description

Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to d...

How the Company Makes Money

Apollomics’ primary business model is typical of clinical-stage biopharmaceutical companies: it seeks to create value by advancing drug candidates through clinical trials and monetizing them via (a) partnering transactions and (b) eventual product co...

Apollomics Financial Statement Overview

Summary

Despite a massive 4192% revenue surge in 2025 and narrowing losses, Apollomics faces severe structural risks. The company suffers from negative stockholders' equity of -$3.18 million, persistent cash burn, and a rapidly contracting asset base, pointing to acute solvency and liquidity concerns that demand external financing.

Income Statement

40Negative

Balance Sheet

20Very Negative

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.50M	8.50M	198.00K	821.00K	323.00K	2,000
Gross Profit	8.50M	8.24M	198.00K	821.00K	323.00K	2,000
EBITDA	-9.36M	-9.22M	-40.77M	-52.88M	-43.29M	-49.59M
Net Income	-10.94M	-10.94M	-53.86M	-172.60M	-240.81M	-94.80M
Balance Sheet
Total Assets	6.71M	6.71M	13.10M	55.39M	76.47M	123.44M
Cash, Cash Equivalents and Short-Term Investments	3.28M	3.28M	9.77M	37.82M	54.61M	94.48M
Total Debt	643.00K	643.00K	966.00K	4.66M	991.00K	325.41M
Total Liabilities	9.90M	9.90M	8.23M	14.15M	524.60M	336.30M
Stockholders Equity	-3.19M	-3.19M	4.86M	41.23M	-448.12M	-212.86M
Cash Flow
Free Cash Flow	-17.99M	-10.37M	-28.77M	-43.22M	-43.19M	-50.86M
Operating Cash Flow	-17.99M	-10.37M	-28.74M	-43.21M	-42.82M	-43.31M
Investing Cash Flow	266.00K	218.00K	5.98M	21.36M	29.05M	-38.95M
Financing Cash Flow	3.59M	3.68M	468.00K	21.23M	-294.00K	-1.64M

Apollomics Technical Analysis

Technical Analysis SentimentNegative

Last Price20.69

Price Trends

50DMA23.33Negative

100DMA20.98Negative

200DMA18.94Positive

Market Momentum

MACD-0.66Positive

RSI42.75Neutral

STOCH24.25Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLM, the sentiment is Negative. The current price of 20.69 is below the 20-day moving average (MA) of 21.38, below the 50-day MA of 23.33, and above the 200-day MA of 18.94, indicating a neutral trend. The MACD of -0.66 indicates Positive momentum. The RSI at 42.75 is Neutral, neither overbought nor oversold. The STOCH value of 24.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APLM.

Apollomics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

APLM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLGN	44Neutral	$7.82M	-0.44	-215.58%	―	-86.76%	16.63%
GDTC	43Neutral	$10.87M	-2.68	-91.37%	―	49.09%	3.91%
XCUR	41Neutral	$6.61M	-0.77	-237.91%	―	―	23.05%
HIND	40Underperform	$12.63M	-0.06	-254.62%	―	-97.99%	99.28%
APLM	39Underperform	$60.31M	-2.73	288.40%	―	―	86.10%

* Healthcare Sector Average

Performance Comparison

APLM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
APLM	Apollomics Inc.	20.69	6.52	46.01%
HIND	Vyome Holdings, Inc.	1.80	-4.51	-71.47%
CLGN	CollPlant Biotechnologies Ltd.	4.13	-18.66	-81.86%
LNAI	Lunai Bioworks, Inc.	0.16	-6.80	-97.65%
XCUR	Exicure	1.01	-3.20	-76.01%
GDTC	CytoMed Therapeutics Limited	0.92	-1.20	-56.70%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026

Apollomics AI Stock Analysis